<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2965">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01454791</url>
  </required_header>
  <id_info>
    <org_study_id>WIRB 20101775</org_study_id>
    <nct_id>NCT01454791</nct_id>
  </id_info>
  <brief_title>Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate</brief_title>
  <official_title>Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients With Multiple Sclerosis Taking Glatiramer Acetate: A Randomized Controlled Double- Blind Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown, Theodore R., M.D., MPH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Neuroscience, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown, Theodore R., M.D., MPH</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of Diclofenac Sodium Topical Gel (DSTG) on
      injection site reaction following self-administer glatiramer acetate in people with Multiple
      Sclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 4 week study with active or placebo medication at randomization and switch treatment at
      2-week crossover visit (2 weeks on each arm). There will be a total of 3 visits to the
      clinic. Subjects will receive instruction on how to apply the DSTG/placebo at the injection
      site and keep a daily injection site reaction diary.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Local Injection Site Reaction (0-6) Scale at Baseline, 2 Weeks</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>patients will complete a daily diary rating their reaction for elements including pain and inflammation or no reaction to all 6 elements listed on the local injection site reaction scale. Range of scores is 0-6 with zero best and 6 worst.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Scale at 2 Weeks</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>0-10 subjective Likert scale for severity of injection site reaction associated pain. Zero is best and 10 is worst</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject Global Impression at 2 Weeks</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>This is a single question: &quot;How would you rate your level of comfort with Copaxone injection during the past two weeks?&quot; Responses include Extremely good, Quite good, Better than average, Average, Below Average, Quite bad, Extremely bad.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Diclofenac Sodium Topical Gel first then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1:1 randomization to either of two treatment phases of 2 weeks duration (active-placebo or placebo-active).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first then Diclofenac Sodium Topical Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1:1 randomization to either of two treatment phases of 2 weeks duration (active-placebo or placebo-active).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diclofenac sodium topical gel</intervention_name>
    <description>diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks either preceded by or followed by two weeks of placebo</description>
    <arm_group_label>Diclofenac Sodium Topical Gel first then Placebo</arm_group_label>
    <arm_group_label>Placebo first then Diclofenac Sodium Topical Gel</arm_group_label>
    <other_name>Voltaren gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>a placebo gel is applied 1-4 times per day for two weeks.</description>
    <arm_group_label>Diclofenac Sodium Topical Gel first then Placebo</arm_group_label>
    <arm_group_label>Placebo first then Diclofenac Sodium Topical Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Multiple Sclerosis (MS) made at least 3 months prior based on McDonald
             or Poser criteria.

          -  Age 18 or more

          -  Ongoing treatment with glatiramer acetate (Copaxone) for three months or more.

          -  No MS exacerbation for 60 days prior to screening.

          -  Mean score of greater than or equal to 1.0 on screening Local Injection Site Reaction
             scale of last 3 days.

          -  Written informed consent.

        Exclusion Criteria:

          -  Regular use of any non-steroidal anti-inflammatory drug (NDAID), except Asprin (&lt;325
             mg daily), between screening and end of study.

          -  Any contraindication to Diclofenac Sodium Topical Gel (DSTG)

               -  allergy to DSTG or any NSAID.

               -  history of asthma, urticaria, or other allergic reaction after taking any NSAID.

          -  Females who are breast feeding, pregnant or have potential to become pregnant during
             the course of the study(fertile and unwilling/unable to use effective contraceptive
             measures).

          -  Cognitive deficits that would interfere with the subject's ability to give informed
             consent or preform study testing.

          -  Any other serious and/or unstable medical condition.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ted R Brown, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>MS Center at Evergreen Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MS Center at Evergreen Healthcare</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <lastchanged_date>February 12, 2015</lastchanged_date>
  <firstreceived_date>August 9, 2011</firstreceived_date>
  <firstreceived_results_date>July 22, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>diclofenac</keyword>
  <keyword>subcutaneous injection</keyword>
  <keyword>glatiramer acetate</keyword>
  <keyword>Copaxone</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Copolymer 1</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diclofenac Sodium Topical Gel Followed by Placebo</title>
          <description>diclofenac sodium topical gel: diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks followed by two weeks of placebo
Placebo: a placebo gel is applied 1-4 times per day for two weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Followed by Diclofenac Sodium Topical Gel</title>
          <description>Placebo for two weeks followed by diclofenac sodium topical gel: diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks
Placebo: a placebo gel is applied 1-4 times per day for two weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20">20 subjects started with Diclofenac, then switched to placebo</participants>
                <participants group_id="P2" count="20">20 subjects started with placebo, then switched to Diclofenac</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diclofenac Sodium Topical Gel Followed by Placebo</title>
          <description>diclofenac sodium topical gel: diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks followed by two weeks of placebo
Placebo: a placebo gel is applied 1-4 times per day for two weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Followed by Diclofenac Sodium Gel</title>
          <description>placebo for 2 weeks followed by diclofenac sodium topical gel: diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks
Placebo: a placebo gel is applied 1-4 times per day for two weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="38"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="33"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Local Injection Site Reaction (0-6) Scale at Baseline, 2 Weeks</title>
        <description>patients will complete a daily diary rating their reaction for elements including pain and inflammation or no reaction to all 6 elements listed on the local injection site reaction scale. Range of scores is 0-6 with zero best and 6 worst.</description>
        <time_frame>2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>The primary outcome is looking at between-intervention differences at 2 weeks of intervention. Not a comparison at any other timepoint</population>
        <group_list>
          <group group_id="O1">
            <title>Diclofenac Sodium Topical Gel</title>
            <description>diclofenac sodium topical gel: diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 2 weeks: a placebo gel is applied 1-4 times per day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Local Injection Site Reaction (0-6) Scale at Baseline, 2 Weeks</title>
            <description>patients will complete a daily diary rating their reaction for elements including pain and inflammation or no reaction to all 6 elements listed on the local injection site reaction scale. Range of scores is 0-6 with zero best and 6 worst.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.39" spread="0.19"/>
                  <measurement group_id="O2" value="3.47" spread="0.19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.45</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.08</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Scale at 2 Weeks</title>
        <description>0-10 subjective Likert scale for severity of injection site reaction associated pain. Zero is best and 10 is worst</description>
        <time_frame>2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>The primary outcome is looking at between-intervention differences at 2 weeks of intervention. Not a comparison at any other timepoint</population>
        <group_list>
          <group group_id="O1">
            <title>Diclofenac Sodium Topical Gel</title>
            <description>diclofenac sodium topical gel: diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 2 weeks: a placebo gel is applied 1-4 times per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pain Scale at 2 Weeks</title>
            <description>0-10 subjective Likert scale for severity of injection site reaction associated pain. Zero is best and 10 is worst</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.44" spread="0.28"/>
                  <measurement group_id="O2" value="2.60" spread="0.28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.6059</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.16</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>not significant</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Global Impression at 2 Weeks</title>
        <description>This is a single question: &quot;How would you rate your level of comfort with Copaxone injection during the past two weeks?&quot; Responses include Extremely good, Quite good, Better than average, Average, Below Average, Quite bad, Extremely bad.</description>
        <time_frame>2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>The secondary outcome is looking at between-intervention differences at 2 weeks of intervention. Not a comparison at any other timepoint</population>
        <group_list>
          <group group_id="O1">
            <title>Diclofenac Sodium Topical Gel</title>
            <description>diclofenac sodium topical gel: diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for two weeks: a placebo gel is applied 1-4 times per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Subject Global Impression at 2 Weeks</title>
            <description>This is a single question: &quot;How would you rate your level of comfort with Copaxone injection during the past two weeks?&quot; Responses include Extremely good, Quite good, Better than average, Average, Below Average, Quite bad, Extremely bad.</description>
            <units>Likert scale 1-7 (7= best)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.68" spread="0.17"/>
                  <measurement group_id="O2" value="4.50" spread="0.17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.705</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.18</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>not significant</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Diclofenac Sodium Topical Gel</title>
          <description>1:1 randomization to either of two treatment phases of 2 weeks duration (active-placebo or placebo-active).
diclofenac sodium topical gel: diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks either preceded by or followed by two weeks of placebo
Placebo: a placebo gel is applied 1-4 times per day for two weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>1:1 randomization to either of two treatment phases of 2 weeks duration (active-placebo or placebo-active).
diclofenac sodium topical gel: diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks either preceded by or followed by two weeks of placebo
Placebo: a placebo gel is applied 1-4 times per day for two weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Theodore R, Brown, MD Principle Investigator</name_or_title>
      <organization>MS Center at Evergreenhealth Care</organization>
      <phone>425-899-5350</phone>
      <email>trbrown@evergreenhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
